Abstract:Cancer encompasses many different diseases, all typically involving an accumulation of genetic alterations. However, despite the genomic complexity of this group of diseases, cancer genomic studies typically rely on sequence alignment to a "reference genome" prior to analysis. Such approaches can provide gene expression quantification of known, annotated genes. However, they miss the detection of fusion genes, novel transcripts, virus insertions, and other genetic insults that may be present in cancer beyond an altered gene expression profile. Here, we develop a workflow for de novo identification and quantification of "outside of reference genome" genetic aberrations. This workflow leverages klue, a method we developed that is based on the compact de Bruijn graph, which can extract sequences uniquely found in a "tumor" sample but not in a "normal" control sample from genomic sequencing data. We first applied this method to an RNA-seq experiment from the EμSRα-tTA/TetO-MYC mouse model, which is a MYC-driven autochthonous transgenic mouse model of T-cell acute lymphoblastic lymphoma (T-ALL). We extracted k-mer contigs present in the mouse tumor samples but are present neither in the spleens of wild-type mice of the same genetic background nor in the standard mouse reference genome assembly. We then mapped RNA-seq reads from the T-ALL mouse tumor samples to these contigs. The contigs with the highest number of mapped reads (i.e. the highest counts) were run through BLAST to determine their identities. The mapped contigs with the highest counts were the tTA transgenic element sequence and the human MYC transgene. This result showcases this workflow's success in isolating and quantifying "reference-absent" tumor-unique sequences. Next, we applied klue to whole genome sequencing (WGS), whole exome sequencing (WES), and RNA-seq data from a patient with B-cell follicular lymphoma (with matched normal specimen) from the Texas Cancer Research Biobank, as this data is unrestricted open access. Tumor-unique contigs in sequencing reads were extracted and analyzed with BLAST and BLAT. In one case, a nonsynonymous point mutation in the SPI1 (also known as PU.1) oncogene was found. The sequencing reads from the tumor sample showed both the "normal variant" of SPI1 as well as the mutant SPI1:H268P, suggesting a heterozygous mutation. Altogether, these results suggest that the idea of first identifying tumor-unique sequences then doing post hoc analysis of those sequences is a viable approach for de novo mutation discovery in cancer genomics. Citation Format: Delaney K. Sullivan, Eissa Albinali, Mayuko Boffelli, Lior Pachter. De novo mutation discovery in a mouse model and a human patient sample of non-Hodgkin's lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6246.

A framework for the interpretation of de novo mutation in human disease

Genome-wide patterns and properties of de novo mutations in humans

The mutational constraint spectrum quantified from variation in 141,456 humans

A Bayesian framework for de novo mutation calling in parents-offspring trios

A familial, telomere-to-telomere reference for human de novo mutation and recombination from a four-generation pedigree

Gene4Denovo: an Integrated Database and Analytic Platform for De Novo Mutations in Humans

Capturing All Disease-Causing Mutations for Clinical and Research Use: Toward an Effortless System for the Human Variome Project

A Statistical Framework for Mapping Risk Genes from De Novo Mutations in Whole-Genome-Sequencing Studies

Real-Time Resolution Of Point Mutations That Cause Phenovariance In Mice

Understanding large scale sequencing datasets through changes to protein folding

De novo rates of a Trypanosoma-resistant mutation in two human populations

High-throughput oncogene mutation profiling in human cancer

Widespread Macromolecular Interaction Perturbations in Human Genetic Disorders

The impact of ancestral, environmental and genetic influences on germline de novo mutation rates and spectra

De novo mutations in moderate or severe intellectual disability

Deep Mutational Scanning in Disease-related Genes with Saturation Mutagenesis-Reinforced Functional Assays (SMuRF)

Abstract 6246: De novo mutation discovery in a mouse model and a human patient sample of non-Hodgkin's lymphoma

Meta-analysis of 46,000 germline de novo mutations linked to human inherited disease

Customized De Novo Mutation Detection for Any Variant Calling Pipeline: SynthDNM.

A Generalizable Deep Learning Framework for Inferring Fine-Scale Germline Mutation Rate Maps

Interpretation of cancer mutations using a multiscale map of protein systems